Screener
Immunome IMNM EBIT
EBIT at other companies
Other financials
Where this comes from
Calculated from Immunome’s reported figures.
The source filing: Immunome’s 10-Q, filed May 12, 2026. Open the filing →
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
FAQ
- What is Immunome's EBIT?
- Immunome (IMNM) reported EBIT of -$59.33M in Q1 2026.
- How has Immunome's EBIT changed year-over-year?
- Immunome's EBIT decreased by 32.9% year-over-year, from -$44.64M to -$59.33M.
- What is the long-term trend for Immunome's EBIT?
- Over 4 years (2021 to 2025), Immunome's EBIT has grown at a 72.7% compound annual growth rate (CAGR), from -$25.2M to -$224.11M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Immunome's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude